Investigational drug · Phase 3
tinengotinib
Also called: TT-00420
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
13
Any phase or sponsor naming "tinengotinib"
First trial start
2023
Nov 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "tinengotinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer (CRPC)
- Cholangiocarcinoma
- Hepatocellular Carcinoma (HCC)
- Breast Cancer
- Intrahepatic Cholangiocarcinoma (Icc)
- Advanced Cholangiocarcinoma
- Cholangiocarcinoma Metastatic
Approved drugs for the same conditions: Breast cancer · Prostate cancer · Liver cancer (hepatocellular carcinoma) · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "tinengotinib" as an intervention, largest first.
TransThera Sciences (Nanjing), Inc.Industry
NCT04742959 · 203 participants · Start Mar 14, 2021 · Primary completion Feb 20, 2024
Drug: TT-00420 · For: Advanced Solid Tumor; Cholangiocarcinoma; HER2-negative Breast Cancer and 8 more
Sites: Duarte, California; Chicago, Illinois; New Brunswick, New Jersey · 6 sites in all
- Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in CholangiocarcinomaPivotal-lookingActive, not recruiting
TransThera Sciences (Nanjing), Inc.Industry
NCT05948475 · 200 participants (planned) · Start Dec 20, 2023 · Primary completion Dec 2026
Drug: Tinengotinib 8 mg; Tinengotinib 10 mg and 1 more · For: Cholangiocarcinoma
Sites: Santa Monica, California; Stanford, California; Westwood, Los Angeles, California · 87 sites in all
- Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)Pivotal-lookingRecruiting
TransThera Sciences (Nanjing), Inc.Industry
NCT07871110 · 182 participants (planned) · Start Sep 18, 2026 · Primary completion Dec 31, 2028
Drug: tinengotinib 10 mg QD plus darolutamide; tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide and 5 more · For: Prostate Cancer (CRPC)
Sites: Fuzhou, China; Guangzhou, China; Wuhan, China · 16 sites in all
- Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or MutationsPivotal-lookingNot yet recruiting
TransThera Sciences (Nanjing), Inc.Industry
NCT07328919 · 138 participants (planned) · Start Jan 2026 · Primary completion Dec 31, 2029
Drug: TT-00420 (tinengotinib); Oxaliplatin, fluorouracil, calcium folinate, irinotecan, capecitabine · For: Intrahepatic Cholangiocarcinoma (Icc); Advanced Cholangiocarcinoma
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 20 sites in all
- A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.Recruiting
AkesoIndustry
NCT07052253 · 100 participants (planned) · Start Jul 18, 2025 · Primary completion May 10, 2027
Drug: TT-00420 (tinengotinib); AK104 and 1 more · For: Hepatocellular Carcinoma (HCC)
Sites: Wuhan, China
TransThera Sciences (Nanjing), Inc.Industry
NCT07498478 · 94 participants (planned) · Start Mar 17, 2026 · Primary completion Jun 30, 2027
Drug: Tinengotinib at the optimal dose combined with Fulvestrant; Tinengotinib and 1 more · For: Breast Cancer
Sites: Guangzhou, China; Wuhan, China; Changsha, China · 13 sites in all
TransThera Sciences (Nanjing), Inc.Industry
NCT05253053 · 84 participants · Start Apr 13, 2022 · Primary completion Aug 31, 2024
Drug: TT-00420; Combination Product: Atezolizumab and 1 more · For: Advanced Solid Tumor; Cholangiocarcinoma; Biliary Tract Cancer and 8 more
Sites: Wuhu, China; Zhengzhou, China; Changsha, China · 9 sites in all
TransThera Sciences (Nanjing), Inc.Industry
NCT04919642 · 55 participants · Start Dec 7, 2021 · Primary completion Feb 28, 2024
Drug: TT-00420 · For: Cholangiocarcinoma; FGFR2 Fusion; FGFR2 Gene Mutation and 2 more
Sites: Anchorage, Alaska; Duarte, California; Santa Monica, California · 32 sites in all
- Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR InhibitorActive, not recruiting
TransThera Sciences (Nanjing), Inc.Industry
NCT06057571 · 50 participants (planned) · Start Nov 17, 2023 · Primary completion Jul 27, 2025
Drug: TT-00420 (tinengotinib) · For: Cholangiocarcinoma Metastatic
Sites: Hefei, China; Beijing, China; Fuzhou, China · 29 sites in all
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT06457919 · 50 participants (planned) · Start Jun 4, 2024 · Primary completion Jun 2027
Drug: Tinengotinib; abiraterone acetate with prednisone and 1 more · For: Prostate Cancer
Sites: New Haven, Connecticut; Basking Ridge, New Jersey; Middletown, New Jersey · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial.
Piha-Paul SA, Liao CY, Dayyani F, et al. · Clin Cancer Res 2026
- Tinengotinib, an arising option for FGFR inhibitor resistant cholangiocarcinoma.
Voutsadakis IA · J Gastrointest Oncol 2026
- Persistent FGFR pathway dependence: where does tinengotinib fit after FGFR inhibitor therapy in advanced cholangiocarcinoma?
Sasanuma H, Yamaguchi H · J Gastrointest Oncol 2026
- Tinengotinib (TT-00420) inhibits tumor growth and overcomes multidrug resistance in gastrointestinal cancers.
Ma M, Ji C, Zhao B, et al. · Mol Cancer Ther 2026
- The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial.
Zhang P, Niu Z, Guo H, et al. · Nat Commun 2026
- Unravelling Tinengotinib's Mechanistic Landscape in Triple-Negative Breast Cancer Via Network Pharmacology and in Silico Simulation Techniques.
Ali M, Parinandi NL, Rotondo A, et al. · Cell Biochem Biophys 2026
Also in development for Prostate Cancer (CRPC)
- preferred combination of tinengotinibPhase 21 trial
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC)
- selected combination of tinengotinibPhase 21 trial
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.